Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Drugs
921 - 940 of 1,306 Results
-
-
As States Try To Rein In Drug Spending, Feds Slap Down One Bold Medicaid Move
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
-
New Medicare Advantage Tool To Lower Drug Prices Puts Crimp In Patients’ Choices
Federal officials are allowing the private insurance plans to use 鈥渟tep therapy鈥 for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
By Susan Jaffe -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Insurer To Purdue Pharma: We Won’t Pay For OxyContin Anymore
Embattled drugmaker Purdue Pharma defends OxyContin as some insurers are dropping the drug in favor of other abuse-deterrent opioid painkillers.
-
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn't afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
-
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma鈥檚 pricing.
By Emily Kopp and Jay Hancock -
States Looking To Tax Opioids Pin Hopes On November Elections
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
By Jay Hancock and Shefali Luthra -
Giuliani鈥檚 Consulting Firm Helped Halt Purdue Opioid Investigation In Florida
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue鈥檚 marketing of OxyContin.
By Fred Schulte -
Lawmakers Push To Protect Patients And Counter Trump
California legislators approved some significant health care proposals in their rush to meet the Friday end-of-session deadline. They tackled controversial topics, such as making abortion pills available on college campuses, and adopted measures countering Trump administration attacks on the Affordable Care Act.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Ask Us Anything!
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners鈥 questions about health policy and politics.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Opioids, EpiPens And Health Funding
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
-
Rehabilitation Plus Rehab? Jails Dispense Drugs To Treat Inmates鈥 Addictions
Rather than go cold turkey, inmates increasingly have the option to take medication to help beat addiction to opioids and other substances. But some warn these substitute drugs serve as another crutch 鈥 and a costly one at that.
By Anna Gorman -
The Man Who Sold America On Vitamin D 鈥 And Profited In The Process
The doctor most responsible for turning the sunshine supplement into a billion-dollar juggernaut has received hundreds of thousands of dollars from the vitamin D industry, according to government records and interviews.
By Liz Szabo -
Purdue Pharma’s Sales Pitch Downplayed Risks Of Opioid Addiction
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients鈥 right to opioid treatment for pain.
By Fred Schulte -
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 See You In Court!
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner talk about a spate of lawsuits involving the Affordable Care Act, as well as the latest in state and federal efforts regarding the Medicaid program for the poor.
-
Advances In Treating Hep C Lead To New Option For Transplant Patients
The opioid epidemic has increased the number of donated organs. Until recently, though, organs from donors who died of drug overdoses were often discarded because an estimated 30 percent of them were infected with hepatitis C.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.